Shares of IsoRay, Inc. (NYSEMKT:ISR), which develops seed brachytherapy and medical radioisotope applications, are higher for a second straight session after the company announced yesterday that its technology had been used in the treatment of a pediatric patient’s tumor. WHAT’S NOTABLE: IsoRay announced yesterday morning that a doctor in North Carolina had successfully completed the world’s first pediatric implant using the company’s Cesium-131 brachytherapy mesh. The patient was a 12 year old male who was diagnosed with recurrent metastatic Wilms tumor, which is a type of childhood kidney tumor. Radiation therapy was needed in this case to treat the surgical bed, according to the doctor, who added that designing the treatment mesh was done with the assistance of the IsoRay team and that the patient recovered normally and has been discharged home. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $3.08 on last trade day and at the end of the day closed at $3.30. Company price to sales ratio in past twelve months was calculated as 27.56 and price to cash ratio as 28.81. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 279.31%.
BG Medicine, Inc. (NASDAQ:BGMD) announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” to the Company. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood. BG Medicine, Inc. (NASDAQ:BGMD) shares advanced 13.61% in last trading session and ended the day on $1.92. BGMD return on equity ratio is recorded as -505.30% and its return on assets is -95.20%. BG Medicine, Inc. (NASDAQ:BGMD) yearly performance is 2.13%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company’s lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The results are being presented in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares moved up 9.47% in last trading session and was closed at $5.20, while trading in range of $5.02 – $5.51. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) year to date (YTD) performance is -0.76%.
March 13, 2014 — ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) announced financial results for the quarter and year ended December 31, 2013. For the year ended December 31, 2013, the Company incurred a net loss of $8.8 million, or $0.16 per basic and diluted share, compared to a net loss of $14.5 million for the year ended December 31, 2012, or $0.35 per basic and diluted share. The net loss for 2013 includes a credit of $642,000 related to the revaluation of the Company’s warrant derivatives, and a charge of $724,000 for stock-based compensation. The net loss for 2012 included a charge of $2.3 million related to the revaluation of the warrant derivatives, a $397,000 financing charge and a charge of $496,000 for stock-based compensation.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) weekly performance is 19.17%. On last trading day company shares ended up $1.43. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is 16.62%. Analysts mean target price for the company is $5.69.
Leave a Reply